WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD DisclosureItem 7.01
From time to time, Wave Life Sciences Ltd. (the “Company”) presents and/or distributes slides and presentations to the investment community at various industry and other conferences to provide updates and summaries of its business. On September18, 2017, the Company updated its corporate presentation, which is available on the Investors& Media section of the Company’s website at http://ir.wavelifesciences.com/, in order to, among other things, disclose that its sixth development program will be in Duchenne muscular dystrophy (“DMD”) targeting exon 53. This presentation is attached as Exhibit 99.1 and is incorporated by reference herein.
The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 7.01 | Financial Statements and Exhibits. |
|
(d)Exhibits |
Wave Life Sciences Ltd. ExhibitEX-99.1 2 d456839dex991.htm EX-99.1 EX-99.1 Wave Life Sciences September 18,…To view the full exhibit click here
About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)
WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb.
